Dong Wha Pharm signs export agreement of USD 32 million for ‘Zabolante’

Published: 2017-01-19 14:35:36

Updated: 2017-01-19 14:35:36

Dong Wha Pharm(Chairman Do-Joon Yoon) signed a license and supply agreement of the quinolone-type antibody ‘Zabolante,’ the Korea’s 23^rd new drug, to commercialize in 12 countries, like the Middle East and North Africa.

The agreement contains a term to assign the exclusive sales license in 12 MENA(Middle East and North Africa) countries to Novosci Healthcare LLC FZCO, a pharmaceutical importer...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.